Efficacy and safety of irreversible electroporation combined with immunotherapy in treatment of unresectable pancreatic cancer： A Meta-analysis
Journal Title: Journal of Clinical Hepatology - Year 2024, Vol 40, Issue 11
Abstract
[Objective] To systematically review the safety and efficacy of irreversible electroporation （IRE） combined with immunotherapy in patients with unresectable pancreatic cancer. [Methods] This study was conducted according to the PRISMA guideline， with a PROSPERO registration unmber of CRD42024531984. Datebases including PubMed， Embase the Cochrane Library， Web of Science， CNKI， Wanfang Data， and VIP were searched for related articles on IRE combined with immunotherapy for unresectable pancreatic cancer published up to February 2024. The articles were screened and related data were extracted according to the established inclusion and exclusion criteria， and the quality of the articles was assessed. Review Manager 5.3 and Stata 17.0 software were used to perform the meta-analysis. [Results] Six studies were finally included， with three prospective studies， two retrospective studies， and one randomized controlled trial. There were 376 patients with unresectable pancreatic cancer in total， among whom there were 222 patients in the IRE group and 154 patients in the IRE+immunotherapy group. The meta-analysis showed that compared with IRE alone， IRE combined with immunotherapy significantly prolonged progression-free survival （hazard ratio ［HR］=0.82， 95% confidence interval ［CI］： 0.72 — 0.92， P=0.001） and overall survival （HR=0.86， 95%CI： 0.80 — 0.93， P=0.000 1）， increased T lymphocyte count in the patients （mean difference=217.93， 95%CI： 192.87 — 242.99， P<0.000 01）， and improved the immune function of patients. However， there were no significant differences between the two groups in reducing the incidence rate of adverse events （odds ratio ［OR］=1.43， 95%CI： 0.76 — 2.72， P=0.27） and improving the objective remission rate of patients （OR=1.49， 95%CI： 0.87 — 2.56， P=0.15）. [Conclusion] IRE combined with immunotherapy is safe and effective in patients with unresectable pancreatic cancer and can significantly improve overall survival and progression-free survival and enhance immune function， with little effect on objective remission rate and the incidence rate of adverse events.
Authors and Affiliations
Jian YE, Junfeng YANG, Liwen DU, Jiansheng LIU
Keywords
Related Articles
- EP ID EP753502
- DOI 10.12449/JCH241122
- Views 18
- Downloads 1
Efficacy and safety of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients with previous direct-acting antiviral agent failure
[Objective] To investigate the efficacy and safety of sofosbuvir/velpatasivr/voxilaprevir （SOF/VEL/VOX） in patients with HCV infection experiencing failure in previous direct-acting antiviral agent （DAA） therapy. [Me...
Establishment of a risk model based on immunogenic cell death-related genes and its value in predicting the prognosis and tumor microenvironment characteristics of hepatocellular carcinoma
[Objective] To identify immunogenic cell death （ICD）-related genes in hepatocellular carcinoma （HCC）， and to establish a scoring model based on these genes for predicting the prognosis and tumor microenvironment cha...
Effectiveness of fibrosis-4 versus aspartate aminotransferase-to-platelet ratio index in evaluating liver fibrosis degree in patients with chronic HBV infection
[Objective] To investigate the performance of fibrosis-4 （FIB-4） versus aspartate aminotransferase-to-platelet ratio index （APRI） in predicting advanced liver fibrosis and disease progression in patients with chronic...
Mechanism of action of disulfidptosis in nonalcoholic fatty liver disease
Disulfidptosis is a novel pattern of cell death caused by disulfide stress and inadequate NADPH. Nonalcoholic fatty liver disease （NAFLD） is a group of metabolic diseases with the main pathological feature of fatty inf...
Systemic therapy for advanced hepatocellular carcinoma
Hepatocellular carcinoma （HCC） is one of the most common malignancies with high morbidity and mortality rates worldwide. With the advances in molecular biology and tumor immunology， molecular-targeted agents represent...